Bulletin
Investor Alert

New York Markets Open in:

March 5, 2021, 7:55 a.m. EST

NIH stops clinical trials for two experimental antibody COVID-19 treatments

The National Institutes of Health said Thursday that it stopped enrollment in two clinical trials evaluating experimental COVID-19 therapies after discovering they likely do not provide a benefit to hospitalized patients. The treatment candidates are GlaxoSmithKline (NYS:GSK) and Vir Biotechnology Inc.'s (NAS:VIR) monoclonal antibody therapy and the privately held Brii Biosciences Inc.'s monoclonal antibody cocktail. Vir told investorson Thursday that the NIH had notified the company about stopping the trial. There were no safety concerns for either therapy. Over the past year, GSK's stock is down 20.0% and shares of Vir tumbled 9.4%, while the broader S&P 500 (S&P:SPX) has rallied 20.4%.

Link to MarketWatch's Slice.